Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Disinfection in Boiling SDS Should Be Made Obligatory to Prevent Secondary Infection of CJD
September 24, 2007
-
ARCHIVE Korosho to Encourage Innovation While Optimizing Healthcare Expenditures: Mr Erikawa
September 24, 2007
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
September 24, 2007
-
ARCHIVE Benefits of Research Must Be Returned to the People: Mr Toguchi
September 24, 2007
-
ARCHIVE New Sales Strategy Going Extremely Well: Mr Kashiwagi of sanofi-aventis
September 24, 2007
-
ARCHIVE Breast Cancer Will Be One of the Major Topics in Women's Health Week: Mr Nishiyama
September 24, 2007
-
ARCHIVE AltaCare Provides Int. Sales, Business Dev. Services for Pharma, Consumer Care Products
September 24, 2007
-
ARCHIVE REGULATORY NEWS IN BRIEF
September 24, 2007
-
ARCHIVE Eli Lilly Enters GP Market with Cialis
September 24, 2007
-
ARCHIVE Boehringer Ingelheim to Initiate PIII Study for BIBW2992
September 24, 2007
-
ARCHIVE Taiyo Yakuhin's Outsourcing Study Group Focuses on Barrier Isolators
September 24, 2007
-
ARCHIVE 303 Orphan Drugs under Development in US
September 24, 2007
-
ARCHIVE Boehringer Ingelheim Ties Up with Ablynx for Nanobody Therapeutics
September 24, 2007
-
ARCHIVE Takara Bio Licenses Anticancer Immunotherapy to Korean Company
September 24, 2007
-
ARCHIVE Nihon Medi-Physics, Nippon Kayaku to Handle Metastron of GE Healthcare
September 24, 2007
-
ARCHIVE Environment Assuring Rapid Supply of New Anticancer Drugs Needed
September 24, 2007
-
ARCHIVE NBI Moves Its Tokyo Office to Osaki
September 24, 2007
-
ARCHIVE Development of New PPAR Agonists Extremely Difficult: Dr Obayashi
September 24, 2007
-
ARCHIVE Innovex, So-net M3 to Provide MR Activities Assessing Service
September 24, 2007
-
ARCHIVE Need to Legalize GL on Clinical Research Stressed by Committee Members
September 24, 2007
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…